中国药业2017，Vol.26Issue(4)：38-40,3.DOI:10.3969/j.issn.1006-4931.2017.04.010
吸入型糖皮质激素联合孟鲁司特治疗儿童咳嗽变异性哮喘的药物经济学评价
Pharmacoeconomical Analysis of Inhaled Glucocorticosteroids Combined with Montelukast in Treating Children with Cough Variant Asthma
摘要
Abstract
Objective To discuss the clinical efficacy and pharmacoeconomics of inhaled glucocorticosteroids(ICS) combined with montelukast treating children with cough variant asthma(CVA),in order to provide the reference for reasonable and economic drug-use of clinic treating children with CVA. Methods 215 cases of children with CVA were divided into A,B,C groups according to random number table method in the hospital from October 2014 to December 2015. The groups A,B,C were respectively given Budesonide Aerosol(200-800 μg/day,twice per day),Fluticasone Propionate Aerosol(50-100 μg/time,twice per day),Beclometasone Dipropionate Aerosol(50-100 μg/time,three times per day)on the base of montelukast(4 mg or 5 mg/time,once a day). The clinical efficacy and cost-effectiveness were evaluated after 12 weeks of treatment. Results The total clinical effective rates of group A,B,C were 92. 86%,96. 00%,94. 29%,respectively and there was no statistically significant difference(P > 0. 05). The per capita cost of group A,B,C was 966. 68 yuan,1079. 20 yuan,949. 14 yuan,respectively and group C has the lowest cost-effectiveness ratio(C/ E=10. 07). Conclusion Beclometasone Dipropionate Aerosol combined with montelukast has better efficacy and economy in treating of children with CVA,which is worthy of clinical promotion.关键词
吸入型糖皮质激素/孟鲁司特/咳嗽变异性哮喘/儿童/临床疗效/药物经济学Key words
inhaled glucocorticosteroids(ICS)/montelukast/cough variant asthma(CVA)/children/clinical efficacy/pharmacoeconomics分类
医药卫生引用本文复制引用
李翠兵,陈穗琛..吸入型糖皮质激素联合孟鲁司特治疗儿童咳嗽变异性哮喘的药物经济学评价[J].中国药业,2017,26(4):38-40,3.基金项目
2015年广东省深圳市南山区卫生科技项目(2015056). （2015056）
